Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Stand-Alone Rx Plans Will Be Available "Everywhere," McClellan Says

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS will set up a Part D bidding system that will get to the highest level of risk that the market will accept, Administrator McClellan says. "Smaller regions" could encourage drug plan sponsors that are unwilling to take on large capacity, he says.

You may also be interested in...



Caremark To Join Medco In Applying To Be National Medicare Rx Sponsor

Assuming both PBMs are approved as national Part D sponsors, there will be no need for “fallback” plans in 2006. Caremark, like Medco, is stressing a desire to sell Part D through health plan and employer clients.

Caremark To Join Medco In Applying To Be National Medicare Rx Sponsor

Assuming both PBMs are approved as national Part D sponsors, there will be no need for “fallback” plans in 2006. Caremark, like Medco, is stressing a desire to sell Part D through health plan and employer clients.

Caremark May Offer Medicare Rx Plan If Risk Is Minimized, CEO Says

The risk corridor currently envisioned for stand-alone drug plans is too wide for Caremark to participate, but the PBM will consider offering a plan if the risk corridor is narrowed. Caremark also wants to avoid being perceived as a competitor by its health plan clients.

Related Content

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel